The American Cancer Society Cancer Action Network penned a letter Dec. 4 to 21 members of Congress requesting they increase agency resources to improve risk assessment for potential shortages and coordinate supply chain resilience efforts as short-term solutions.
Because drug shortages are complex, the cancer society also proposed long-term solutions, including incentivizing manufacturers to improve quality with ratings and supporting pharmaceutical facility upgrades.
The organization also recommended the legislators review government policies that enforce “extraordinarily low-cost sterile injectables” to remain at their cheap cost — which inadvertently discourages drugmakers from fortifying safety nets for tentative shortages of common sterile injectables.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
